Skip to main navigation Skip to search Skip to main content

A Phase 2 Open-Label Study to Determine the Effects of Blinatumomab on Minimal Residual Disease in Subjects with high-risk Diffuse Lage B-Cell Lymphoma Post-autologous Hematopoietic Stem-Cell Transplantation

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/SVHM/166
NMA SSA Reference Number: SSA/18/MonH/89
Monash Health Ref: RES-18-0000-100X
StatusFinished
Effective start/end date20/05/19 → 19/05/24

Keywords

  • treatment efficacy
  • clinical trial
  • b-cell lymphoma

Clinical Trial Phase

  • Phase II